Abstract: . . .  during therapy. J Clin Oncol 2001;19:2534-41. 23. Einhorn LH. Treatment of testicular cancer : a new and improved model. J Clin Oncol 1990;8:1777-81. 24. Diseases and abnormalities of the placenta. In: Cunningham FG, et al., eds. Williams Obstetrics. 21st ed. New York: McGraw-Hill, 2001:835-47. 25. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer : a pilot randomised controlled trial. Lancet 1999;353:1207-10. 26. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer : screening, treatment, and follow-up. Gynecol Oncol 1994;55(3 pt 2):S4-14. 27. Malkasian GD Jr, Knapp RC, Lavin PT, Zurawski VR Jr, Podratz KC, Stanhope CR, et al. Preoperative evaluation of serum CA 125 lev- els in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159:341-6. 28. Bridgewater JA, Nelstrop AE, Rustin GJ, Gore ME, McGuire WP, Hoskins WJ. Comparison of standard and CA-125 response crite- ria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 1999;17:501-8. 29. Crawford ED, Schutz MJ, Clejan S, Drago J, Resnick MI, Chodak GW, et al. The effect of digital rectal examination on prostate-spe- cific antigen levels. JAMA 1992;267:2227-8. 30. Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finas- teride on prostate specific antigen: review of available data. J Urol 1996;155:3-9. 31. Carter . . .
. . .  receiver operating char- acteristic curve. Am J Gastroenterol 1999;94:1941-6. 19. Tang ZY, Yu YQ, Zhou XD, Yang BH, Ma ZC, Lin ZY. Subclinical hepatocellular carcinoma: an analysis of 391 patients. J Surg Oncol Suppl 1993;3:55-8. 20. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31:330-5. 21. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers . International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15:594-603. 22. Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ. Predicting outcome to chemotherapy in patients with germ cell tumors : the value of the rate of decline of human chorionic gonadotropin and alpha-fetoprotein during therapy. J Clin Oncol 2001;19:2534-41. 23. Einhorn LH. Treatment of testicular cancer : a new and improved model. J Clin Oncol 1990;8:1777-81. 24. Diseases and abnormalities of the placenta. In: Cunningham FG, et al., eds. Williams Obstetrics. 21st ed. New York: McGraw-Hill, 2001:835-47. 25. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer : a pilot randomised controlled trial. Lancet 1999;353:1207-10. 26. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer : screening, treatment, and follow-up. Gynecol Oncol 1994;55(3 pt 2):S4-14. 27. Malkasian GD . . .
--3000,2,750,3161,37383